Investigators sought to determine whether digital breast tomosynthesis is a more effective screening modality vs 2-dimensional digital mammography in breast cancer survivors.
The ARC-8 study evaluated whether AB680, the anti-PD-1 antibody zimberelimab, and chemotherapy could improve metastatic pancreatic adenocarcinoma (PDAC) outcomes.
Investigators examined EGFR expression patterns in a cohort of patients with malignant mesothelioma.
This retrospective study reviewed small cell transformation (SCT) cases from the past 2 years to investigate the phenomenon of pseudo-SCT.
Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
The phase 1b/2 PLANET study tested the combination of lanreotide and pembrolizumab in advanced well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
This post hoc analysis of KEYNOTE-240 was performed to determine whether objective response at landmark is prognostic of longer survival after landmark time.
Investigators of the SUMMIT basket trial evaluated the efficacy of neratinib both as a monotherapy and in combination with other agents in patients with fibrolamellar carcinoma (FLC).
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
